Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19.
- Sector(s): Healthcare
- Industry: Biotechnology
- Full Time Employees: 39
- Incorporated in 2012
- Headquartered in Boston, Massachusetts
- https://ateapharma.com/
Atea Pharmaceuticals upsized offering by 1.5 mln shares and prices 12.5 mln share IPO at $24.00 per share, at the high end of the $22-24 expected range
No comments:
Post a Comment